



Washington State Health Care Authority
Prescription Drug Program

1511 3rd Ave Suite 523 • Seattle, Washington 98101

206-521-2029 • <http://hca.wa.gov/about-hca/prescription-drug-program>

October 28, 2016

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority (Medicaid/Uniform Medical Plan) and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective dates:

- Medicaid- September 30, 2016
- Uniform Medical Plan- October 24, 2016
- Labor and Industry- January 1, 2017

Hepatitis C – Direct-acting Antivirals reviewed 8/17/2016		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
ledipasvir/sofosbuvir	Harvoni [®] tablet	PA required	PA required	Yes
sofosbuvir	Sovaldi [®] tablet	PA required	PA required	Yes
sofosbuvir/velpatasvir	Epclusa [®] tablet	PA required	PA required	Yes
The effect of this recommendation is to add Epclusa [®] as preferred on the PDL.				

Each agency will use the common PDL according to its benefit structure. You may view the current PDL at: <http://hca.wa.gov/about-hca/prescription-drug-program/reports>.

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at leta.evaskus@hca.wa.gov.

Sincerely,

Ray Hanley
Prescription Drug Programs Director
Washington State Health Care Authority